Ligand Pharmaceuticals LGND Rylaze — Total revenues and income

Other product segments

Similar metrics at other companies

JAZZRylaze/Enrylaze — Revenue from Contract with Customer, Excluding Assessed Tax

$103.7M+10.1%

PTH

PTHSLicense and collaboration revenues — Total Revenue

$241K—

QTRXCollaboration and license revenue — Total revenues

$560K-27.4%

QTRXService and other revenue — Total revenues

$10.38M+17.6%

SNDAResident revenue — Total revenues

$108.43M+36.8%

ASSTOther revenue — Total revenues

$43K+514%

FAQ

What is Ligand Pharmaceuticals's rylaze — total revenues and income?

Ligand Pharmaceuticals (LGND) reported rylaze — total revenues and income of $3.2M in Q2 2026.

How has Ligand Pharmaceuticals's rylaze — total revenues and income changed year-over-year?

Ligand Pharmaceuticals's rylaze — total revenues and income increased by 11.8% year-over-year, from $2.86M to $3.2M.

What does rylaze — total revenues and income mean?

This metric represents the aggregate financial inflows generated by the Rylaze product line, including both direct product sales and associated milestone or licensing payments. It serves as a key indicator of the commercial performance and market adoption of this specific therapeutic asset within the company's portfolio. Tracking this figure allows investors to assess the revenue contribution and growth trajectory of the asset independent of the broader corporate financial results.